CIC
IBB icon

Carnegie Investment Counsel’s iShares Biotechnology ETF IBB Stock Holding History

Carnegie Investment Counsel’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,670
Closed -$238K – 301
2015
Q4 		$238K Sell
2,670
-30
-1% -$3.26K 0.04% 260
2015
Q3 		$295K Buy
+2,700
New +$324K 0.05% 244

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Carnegie Investment Counsel's IBB Position: Q1 2016 in Review

Carnegie Investment Counsel sold out of iShares Biotechnology ETF (IBB) in Q1 2016, closing a stake of 2,670 shares — an estimated $238K sold.

Carnegie Investment Counsel first reported a position in IBB in Q3 2015 and held it in 2 quarters. The position peaked at $295K in Q3 2015. 415 funds tracked by Wall St. Rank hold IBB as of Q1 2016.

  • Carnegie Investment Counsel reported no remaining iShares Biotechnology ETF position as of Q1 2016 after selling out during the quarter.
  • Carnegie Investment Counsel sold 2,670 iShares Biotechnology ETF shares in Q1 2016, an estimated $238K.
  • Carnegie Investment Counsel first reported a position in iShares Biotechnology ETF in Q3 2015 and held it in 2 quarters.
  • Carnegie Investment Counsel's iShares Biotechnology ETF position peaked at $295K in Q3 2015.
  • 415 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2016.

Based on Carnegie Investment Counsel's 13F filing for Q1 2016, filed 13 Apr 2016.